You are here: Industry Insights > NICE

News List

NICE recommends UCB's Cimzia in severe plaque psoriasis pharmafiles
April 23, 2019
NICE has announced its decision to recommend UCB Pharma’s Cimzia (certolizumab pegol) for use on the NHS in England in the treatment of severe plaque psoriasis in patients who have failed to respond to, or are unsuitable for, other systemic treatments.
NICE final guidance published for Cimzia pharmatimes
April 21, 2019
The National Institute for Health and Care Excellence (NICE) has shared its final guidance for the recommended use of UCB’s Cimzia (certolizumab pegol).
Ionis' Tegsedi gets a U.K. boost after NICE reverses initial guidance fiercepharma
April 18, 2019
The path for Ionis’ Tegsedi in the U.K. looked rocky after a preliminary “no” last year from England's drug-price watchdog.
‘Landmark’ day for Akcea as NICE recommends Tegsedi in rare inherited hATTR pharmatimes
April 18, 2019
The National Institute of Health and Care Excellence (NICE) has issued draft highly specialised technologies guidance……
NICE recommends BMS’ Opdivo-Yervoy combination for RCC pharmaceutical-technology
April 09, 2019
Bristol-Myers Squibb (BMS) has announced that the National Institute of Health and Care Excellence (NICE) has recommends Opdivo (nivolumab) and...
AZ' Imfinzi to be funded for NHS use via CDF pharmatimes
April 02, 2019
The National Institute for Health and Care Excellence (NICE) has recommended funding for use of AstraZeneca’s Imfinzi (durvalumab) on the NHS via the Cancer Drugs Fund.
NICE refuses to endorse Biomarin’s Batten disease drug pharmaceutical-technology
February 26, 2019
The UK National Institute for Health and Care Excellence (NICE) has published a draft guidance saying that Biomarin’s therapy for Batten disease, Brineura (cerliponase alfa), cannot be recommended for use in the National Health Service (NHS)....
Swayed by discounts, NICE finally backs Roche's Perjeta for postsurgery breast cancer fiercepharma
February 24, 2019
Looks like the third time was a charm for Roche’s Perjeta when it comes to postsurgery treatment of HER2-positive breast cancer in England.
NICE says drug to treat Batten disease cannot be recommended for NHS use because company is unable to address concerns about long-term effectiveness firstwordpharma
February 23, 2019
NICE has published draft guidance which confirms its earlier decision not to recommend cerliponase alfa (also called Brineura and made by Biomarin) for children with Batten disease - a very rare inherited condition affecting between 1 and 6 babies each ye
NICE backs Takeda’s Alunbrig in second-line lung cancer pharmaceutical-technology
February 20, 2019
The UK’s pricing regulator the National Institute of Health and Care Excellence (NICE) has revised its previous rejection of Takeda’s Alunbrig (brigatinib) for adults with anaplastic lymphoma kinase ....

Previous page 1 2 3 4 5 6 7 8 9 10 ... 41 42 Next page